2022
Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List?
Perazella MA, Juncos LA. Drug-Induced Osmotic Nephropathy: Add SGLT2-Inhibitors to the List? Kidney360 2022, 3: 550-553. PMID: 35582186, PMCID: PMC9034826, DOI: 10.34067/kid.0007882021.Peer-Reviewed Original ResearchHumansKidneyKidney DiseasesOsmosisSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors
2020
SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAcute Kidney InjuryDiabetes Mellitus, Type 2HumansPharmaceutical PreparationsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure